HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Israel, O. Articles by Epelbaum, R. Search for Related Content PubMed PubMed Citation Articles by Israel, O. Articles by Epelbaum, R.

Is ¹⁸F-FDG PET/CT Useful for Imaging and Management of Patients with Suspected Occult Recurrence of Cancer?

¹ Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel
² The B. Rappaport School of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
³ Department of Diagnostic Imaging, Rambam Medical Center, Haifa, Israel
⁴ Department of Oncology, Rambam Medical Center, Haifa, Israel

Rising serum tumor markers may be associated with negative imaging in the presence of cancer. CT and ¹⁸F-FDG PET may yield incongruent results in the assessment of tumor recurrence. The present study evaluates the incremental role of ¹⁸F-FDG PET/CT for the diagnosis and management of cancer patients with increasing levels of tumor markers as the sole indicator of potential recurrence after initial successful treatment. Methods: Thirty-six cancer patients with increasing levels of tumor markers during follow-up and negative CT underwent ¹⁸F-FDG PET/CT, which showed 111 sites of increased tracer uptake. PET/CT was compared with PET results on a site-based analysis for characterization of ¹⁸F-FDG foci and on a patient-based analysis for diagnosis of recurrence. The clinical impact of PET/CT on further patient management was evaluated. Results: Thirty patients (83%) had recurrence in 85 malignant sites (77%). For the site-based analysis, PET had a sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 96%, 50%, 85%, 85%, and 82%, respectively, as compared with the performance indices of PET/CT of 100%, 89%, 97%, 97%, and 100%, respectively. There was a statistically significant difference between the specificity (P < 0.05) and accuracy (P < 0.001) of PET and PET/CT for precise characterization of suspected lesions. For the patient-based analysis, PET had a sensitivity, specificity, and accuracy of 93%, 50%, and 86%, respectively, as compared with PET/CT with values of 93%, 67%, and 89%, respectively (P = not significant). PET/CT was the single modality that directed further management and treatment planning in 12 patients (33%). Conclusion: The results of this study indicate that PET/CT may improve the accuracy of occult cancer detection and further lead to management changes in patients with increasing levels of tumor markers as the sole suspicion of recurrent malignancy.

Key Words: PET • PET/CT • cancer recurrence • tumor markers

Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8a-9a. [Full Text]  

This article has been cited by other articles:

				S. Badiee, B. L. Franc, E. M. Webb, B. Chu, R. A. Hawkins, and F. Coakley Role of IV Iodinated Contrast Material in 18F-FDG PET/CT of Liver Metastases Am. J. Roentgenol., November 1, 2008; 191(5): 1436 - 1439. [Abstract] [Full Text] [PDF]

				J. B. Roedl, M. G. Harisinghani, R. R. Colen, A. J. Fischman, M. A. Blake, D. J. Mathisen, and P. R. Mueller Assessment of Treatment Response and Recurrence in Esophageal Carcinoma Based on Tumor Length and Standardized Uptake Value on Positron Emission Tomography-Computed Tomography Ann. Thorac. Surg., October 1, 2008; 86(4): 1131 - 1138. [Abstract] [Full Text] [PDF]

				H. Guo, H. Zhu, Y. Xi, B. Zhang, L. Li, Y. Huang, J. Zhang, Z. Fu, G. Yang, S. Yuan, et al. Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus J. Nucl. Med., August 1, 2007; 48(8): 1251 - 1258. [Abstract] [Full Text] [PDF]

				W. De Wever, Y. Vankan, S. Stroobants, and J. Verschakelen Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer Eur. Respir. J., May 1, 2007; 29(5): 995 - 1002. [Abstract] [Full Text] [PDF]

				A. Shammas, B. Degirmenci, J. M. Mountz, B. M. McCook, B. Branstetter, B. B. Bencherif, J. M. Joyce, S. E. Carty, H. A. Kuffner, and N. Avril 18F-FDG PET/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer J. Nucl. Med., February 1, 2007; 48(2): 221 - 226. [Abstract] [Full Text] [PDF]

				O. Israel and A. Kuten Early Detection of Cancer Recurrence: 18F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care J. Nucl. Med., January 1, 2007; 48(1_suppl): 28S - 35S. [Abstract] [Full Text] [PDF]

				M. E. Juweid and B. D. Cheson Positron-Emission Tomography and Assessment of Cancer Therapy N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507. [Full Text] [PDF]

				H. Schoder, H. W.D. Yeung, and S. M. Larson CT in PET/CT: Essential Features of Interpretation J. Nucl. Med., August 1, 2005; 46(8): 1249 - 1251. [Full Text] [PDF]

				O. Israel, N. Yefremov, R. Bar-Shalom, O. Kagana, A. Frenkel, Z. Keidar, and D. Fischer PET/CT Detection of Unexpected Gastrointestinal Foci of 18F-FDG Uptake: Incidence, Localization Patterns, and Clinical Significance J. Nucl. Med., May 1, 2005; 46(5): 758 - 762. [Abstract] [Full Text] [PDF]